+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronary Stents Market Size, Share & Trends Analysis Report by Product (Bare Metal Stents, Drug Eluting Stents, Bioresorbable Vascular Scaffold), by Region (North America, Europe, APAC, Latin America, MEA), and Segment Forecasts, 2020 - 2027

  • ID: 4538775
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • B Braun Melsungen AG
  • Biotronik
  • C. R. Bard, Inc.
  • Cook Medical
  • Medtronic
  • MORE
The global coronary stents market size is expected to reach USD 11.3 billion by 2027, expanding at a CAGR of 4.7%. Increasing adoption of minimally invasive surgeries and percutaneous coronary intervention (PIC) procedures is expected to drive the market for coronary stents in the coming years. Moreover, increasing geriatric population is considered as a high impact rendering driver for the growth of this industry over the forecast period. Technological advancement in 2nd generation drug eluting stents (DES) is further fueling the growth. Development of biodegradable and polymer free DES in order to increase patient compliance is expected to drive the market over the coming years.

The coronary stent market is driven by reimbursement coverage provided by the general public Center for Medicare and Medicaid Services (CMS) and private payers. The coverage is availed under national coverage determination for carotid artery stenting, including products and service provider. From January 2020, Centers for Medicare & Medicaid Services (CMS) proposed reimbursement for some angioplasty and stenting procedures performed in ambulatory surgical center (ASC), which is expected to boost market revenue over the forecast period.

Further key findings from the report suggest:
  • In terms of revenue, the DES dominated the product segment as of 2019. New product launches and technological advancements in 2nd gen DES are acting as the driving factor for this segment
  • Prices for the first-generation BVS (Bioresorbable Vascular Scaffold) are much high as compared to existing BMS (Bare Metal Stent) and DES. Due to its safety concern and high hospitalization rates, doctors are not preferring BRS over DES. Moreover, high crossing profile and bulky struts are factors majorly impeding the BRS market
  • Asia Pacific is expected to exhibit the highest growth rate over the forecast period. Increase in disposable income and growing incidence of heart diseases will fuel market growth in the coming years
  • Some of the key companies present in the coronary stent market are Medtronic, Abbott, Boston Scientific, Terumo Corporation, Biotronik, and Microport Corporation
  • With USD 2.3 billion R&D expenditure in 2018, Abbott is anticipated to provide with technologically advanced second generation DES and may be BVS in near future.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • B Braun Melsungen AG
  • Biotronik
  • C. R. Bard, Inc.
  • Cook Medical
  • Medtronic
  • MORE

Chapter 1 Research Methodology
1.1 Research Methodology
1.2 Information Procurement
1.2.1 Purchased Database:
1.2.2 Internal database
1.2.3 Secondary Sources
1.2.4 Primary Research:
1.2.5 Details Of Primary Research
1.3 Information or Data Analysis
1.3.1 Data Analysis Models
1.4 Market Formulation & Validation
1.5 Model Details
1.5.1 Commodity Workflow Analysis (Model 1)
1.6 List of Secondary Sources
1.7 List of Primary Sources
1.8 Abbreviations
1.9 Report Objectives

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Industry Outlook
3.1 Market Segmentation
3.2 Market Lineage Outlook
3.2.1 Parent Market Analysis
3.2.2 Ancillary Market Analysis
3.3 Market Variable Analysis
3.3.1 Market Driver Analysis
3.3.1.1 Rising burden of Cardiovascular Diseases (CVDs)
3.3.1.2 Government initiatives to reduce the cost of coronary stents
3.3.1.3 Advancements in stenting technologies
3.3.2 Market Restraint Analysis
3.3.2.1 Stringent regulation and approval
3.3.2.2 Product recall and failure
3.3.3 Industry Challenges
3.3.3.1 Risk associated with coronary stent post-procedure
3.4 Penetration & Growth Prospect Mapping
3.5 User Perspective Analysis
3.5.1 Consumer Behavior Analysis
3.5.2 Market Influencer Analysis
3.6 Pricing Analysis
3.7 Technology Overview
3.8 Regulatory Framework
3.8.1 Regulatory Landscape
3.8.2 Reimbursement Framework
3.8.2.1 CPT Coding implications
3.8.2.2 HCPCS Coding implications
3.8.3 Cms New Reimbursement Policy For Pci
3.9 Product Pipeline/Clinical Trial Analysis
3.10 R&D Expenditure Analysis
3.11 Estimated R&D Expenditure On Various Types Of Stents (2014 - 2019)
3.12 Product Recalls
3.13 Business Environment Analysis tools
3.13.1 Swot Analysis, By Pest
3.13.2 Porter’s Five Forces Analysis

Chapter 4 Coronary Stents Market: Competitive Analysis
4.1 Market Participation Categorization
4.2 Competitive Dashboard Analysis
4.3 Innovators
4.4 Recent Innovations
4.5 Public Companies
4.5.1 Company Market Share Analysis
4.5.2 Company Market Position Analysis
4.5.3 Heat Map Analysis
4.6 Vendor Landscape
4.6.1 List Of Coronary Stent Providers

Chapter 5 Product Segment Analysis
5.1 Coronary Stents Market: Product Movement Analysis
5.2 Bare Metal Stents
5.2.1 Bare Metal Stents Market, 2016 - 2027 (USD Million)
5.3 Drug Eluting Stents
5.3.1 Drug Eluting Stents Market, 2016 - 2027 (USD Million)
5.3.2 Biodegradable Drug Eluting Stents
5.3.2.1 biodegradable drug eluting stents market, 2016 - 2027 (USD Million)
5.3.3 Non-Biodegradable Drug Eluting Stents
5.3.3.1 non-biodegradable drug eluting stents market, 2016 - 2027 (USD Million)
5.4 Bioresorbable Vascular Scaffolds
5.4.1 Bioresorbable Vascular Scaffolds Market, 2016 - 2027 (USD Million)

Chapter 6 Coronary Stents Market: Regional Estimates & Trend Analysis, by Product
6.1 Coronary Stents Market Share by Region, 2019 & 2027
6.2 North America
6.2.1 North America Coronary Stents Market, 2016 - 2027 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Coronary Stents market, 2016 - 2027 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Coronary Stents market, 2016 - 2027 (USD Million)
6.3 Europe
6.3.1 Europe Coronary Stents Market, 2016 - 2027 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. coronary stents market, 2016 - 2027 (USD Million)
6.3.3 Germany
6.3.3.1 Germany coronary stents market, 2016 - 2027 (USD Million)
6.3.4 France
6.3.4.1 France coronary stents market, 2016 - 2027 (USD Million)
6.3.5 Italy
6.3.5.1 Italy coronary stents market, 2016 - 2027 (USD Million)
6.3.6 Spain
6.3.6.1 Spain coronary stents market, 2016 - 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Coronary Stents Market, 2016 - 2027 (USD Million)
6.4.2 Japan
6.4.2.1 Japan coronary stents market, 2016 - 2027 (USD Million)
6.4.3 China
6.4.3.1 China coronary stents market, 2016 - 2027 (USD Million)
6.4.4 India
6.4.4.1 India coronary stents market, 2016 - 2027 (USD Million)
6.4.5 South Korea
6.4.5.1 South Korea coronary stents market, 2016 - 2027 (USD Million)
6.4.6 Australia
6.4.6.1 Australia coronary stents market, 2016 - 2027 (USD Million)
6.5 Latin America
6.5.1 Latin America Coronary Stents Market, 2016 - 2027 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil coronary stents market, 2016 - 2027 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico coronary stents market, 2016 - 2027 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina coronary stents market, 2016 - 2027 (USD Million)
6.6 MEA
6.6.1 MEA Coronary Stents Market, 2016 - 2027 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa coronary stents market, 2016 - 2027 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia coronary stents market, 2016 - 2027 (USD Million)
6.6.4 UAE
6.6.4.1 UAE coronary stents market, 2016 - 2027 (USD Million)

Chapter 7 Company Profiles
7.1 Abbott
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Medtronic
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Boston Scientific Corporation
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Terumo Corporation
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 B Braun Melsungen AG
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Biotronik
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Stentys SA
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 MicroPort Scientific Corporation
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 C. R. Bard, Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Cook Medical
7.10.1 Company Overview
7.10.2 Product Benchmarking
7.10.3 Strategic Initiatives

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • Terumo Corporation
  • B Braun Melsungen AG
  • Biotronik
  • Stentys SA
  • MicroPort Scientific Corporation
  • C. R. Bard, Inc.
  • Cook Medical
Note: Product cover images may vary from those shown
Adroll
adroll